
EXALGO Call Center
Phone: 1.888.9EXALGO (1.888.939.2546)
Fax: 1.888.423.3511
Please report all suspected adverse events associated with the use of EXALGO to Covidien Product Monitoring at 1.800.778.7898.
Adverse event information may also be reported to the FDA MedWatch Reporting System by phone at 1.800.FDA.1088 (1.800.332.1088) or by mail using Form 3500 at www.fda.gov/medwatch.
If you have any questions or concerns, you may contact our Product Monitoring department at 1.800.778.7898.
Contact Us (*indicates a required field)
Please see full prescribing information including BOXED WARNING.
PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE IMPORTANT WARNINGS IN THIS LABEL.
WARNING: POTENTIAL FOR ABUSE, IMPORTANCE OF
PROPER PATIENT SELECTION AND LIMITATIONS OF USE
Potential for Abuse
EXALGO contains hydromorphone, an opioid agonist and a Schedule II controlled substance with an abuse liability similar to other opioid analgesics. EXALGO can be abused in a manner similar to other opioid agonists, legal or illicit. These risks should be considered when administering, prescribing, or dispensing EXALGO in situations where the healthcare professional is concerned about increased risk of misuse, abuse, or diversion. Schedule II opioid substances which include hydromorphone, morphine, oxycodone, fentanyl, oxymorphone and methadone have the highest potential for abuse and risk of fatal overdose due to respiratory depression.
Proper Patient Selection
EXALGO is an extended release formulation of hydromorphone hydrochloride indicated for the management of moderate
to severe pain in opioid tolerant patients when a continuous around-the-clock opioid analgesic is needed for an extended
period of time. Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine per day, 25 mcg
transdermal fentanyl/hour, 30 mg of oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg of oral oxymorphone/day
or an equianalgesic dose of another opioid, for a week or longer.
EXALGO is for use in opioid tolerant patients only.
Fatal respiratory depression could occur in patients who are not opioid tolerant.
Accidental consumption of EXALGO, especially in children, can result in a fatal overdose of hydromorphone.
Limitations of Use
EXALGO is not indicated for the management of acute or postoperative pain.
EXALGO is not intended for use as an as needed analgesic.
EXALGO tablets are to be swallowed whole and are not to be broken, chewed, dissolved, crushed or injected. Taking
broken, chewed, dissolved or crushed EXALGO or its contents leads to rapid release and absorption of a potentially fatal dose of hydromorphone.